FDA hits Amicus with delay on 'breakthrough' Pompe drug
AT-GAA, Amicus Therapeutics’ lead Phase III drug for Pompe disease, was at the center of attention during the Q1 call with investors Monday. Execs talked …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
